Oncolytics reports preclinical data on pelareorep with RAS inhibitor

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Oncolytics reports preclinical data on pelareorep with RAS inhibitor

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

September 10, 2026 8:15 AM EDT

Preclinical results demonstrate pelareorep activity is maintained in the presence of RAS inhibition

Findings support further evaluation of pelareoreps potential to deepen and prolong responses to RAS-targeted therapy

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.

During the initial treatment period, when pelareorep was administered every other day,... More